Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $3.53
Previous CloseN/A
Volume775.41K
Average Volume (3M)651.06K
Market Cap
$17.68M
Enterprise Value-$18.68M
Total Cash (Recent Filing)$238.60M
Total Debt (Recent Filing)$682.00K
Price to Earnings (P/E)―
Beta3.40
Next Earnings
May 08, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding58,401,146
10 Day Avg. Volume526,564
30 Day Avg. Volume651,062
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.54
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$5.50Price Target Upside1733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
BioAtla News
PremiumCompany Announcements
BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook
PremiumCompany Announcements
BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe drug was well-tolerated and demonstrated tumor reduction in multiple patients.
Partnership DiscussionsPartnership discussions for Evalstotug are ongoing, with multiple discussions taking place, which could lead to positive developments for the company.
Regulatory ProgressThe FDA has shown support for a pivotal trial in HNSCC for BioAtla's ozuriftamab vedotin, which could potentially lead to accelerated approval.
Bears Say
Development ChallengesThe development of mecbotamab vedotin (BA3011) for both undifferentiated pleomorphic sarcoma and non-small cell lung cancer indications has stalled.
Financial OverhangBioAtla could face a near-term financial overhang with current cash likely insufficient to support completion of a registrational study for its Phase 2 candidates.
Pipeline UncertaintyThere are few meaningful catalysts from the company’s pipeline in the next 12 months, potentially deteriorating its financial strength.
---
Ownership Overview
9.23% Insiders
4.85% Mutual Funds
25.32% Other Institutional Investors
55.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $0.24 and its highest was $3.53 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $17.68M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is May 08, 2025 which is in 23 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Mar 27, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.105.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -0.3.
How many shares outstanding does BioAtla have?
BioAtla has 58,401,146 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went down -5.128%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
---
BioAtla Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (1733.33% Upside)
$5.50 (1733.33% Upside)
Blogger Sentiment
Bullish
BCAB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.98%
12-Months-Change
Fundamentals
Return on Equity
-164.30%
Trailing 12-Months
Asset Growth
-56.19%
Trailing 12-Months
Company Description
BioAtla
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
---
BCAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in BioAtla's clinical programs, particularly in the areas of CAB platform development and Phase 2 clinical programs, showing promising therapeutic potential and favorable response rates. Financial strategies are in place to ensure sustainability and future growth, although there are concerns regarding decreased cash reserves and workforce reductions. Overall, the positive clinical progress and strategic positioning outweigh the financial lowlights.Read More>---
BCAB Stock 12 Month Forecast
Average Price Target
$5.50
▲(1733.33% Upside)
Technical Analysis
Best Analysts Covering BCAB
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-41.40%
reiterated a buy rating 11 months ago
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -41.40% per trade.
---